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Abstract
Problem/Condition: CDC monitors the incidence of mumps in the United States
through the passive reporting of cases to its National Notifiable Disease Surveil-
lance System (NNDSS).
Reporting Period Covered: 1988–1993.
Description of System: Weekly reports to the NNDSS from 48 states and the
District of Columbia were used to calculate incidence rates for mumps. State
immunization requirements were obtained from the U.S. Department of Health
and Human Services. 
Results: After the licensure of mumps vaccine in the United States in December
1967 and the subsequent introduction of state immunization laws in an increas-
ing number of states, the reported incidence of mumps decreased substantially.
The 1,692 cases of mumps reported for 1993 represent the lowest number of
cases ever reported to NNDSS and a 99% decrease from the 152,209 cases re-
ported for 1968. During 1988–1993, most cases occurred in children 5–14 years
of age (52%) and in persons ≥15 years of age (36%). Although the incidence de-
creased in all age groups, the largest decreases (>50% reduction in incidence
rate per 100,000 population) occurred in persons ≥10 years of age. Overall, the
incidence of mumps was lowest in states that had comprehensive school immu-
nization laws requiring mumps vaccination and highest in states that did not
have such requirements.
Interpretation: Because of the extensive use of mumps vaccine and the in-
creased number of states that had enacted mumps immunization laws, the
number of reported mumps cases decreased further since the marked decline
that began during the early 1970s. The earlier shift in incidence from children of
school ages to older persons that was noted during 1985–1988 continued until
1992, when the proportion of cases occurring in children of school ages in-
creased and exceeded the proportions occurring in other age groups. 
Actions Taken: All health-care providers are encouraged to a) report mumps
cases to their local and state health departments for transmission to NNDSS and
b) enact school immunization laws requiring mumps vaccination.
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INTRODUCTION
Mumps vaccine was licensed in the United States in December 1967, and the Advi-
sory Committee on Immunization Practices (ACIP) recommended that its use be
considered for children approaching puberty, for adolescents, and for adults (1 ). At
that time, the public health community considered mumps control a low priority, and
ACIP stated that mumps immunization should not compromise the effectiveness of
established public health programs (1,2 ). In 1972, however, ACIP recommendations
were strengthened to indicate that mumps vaccination was particularly important for
the initially targeted age groups; in 1977, ACIP recommended the routine vaccination
of all children ≥12 months of age. The use of mumps vaccine in young children was
facilitated by the introduction (in 1977) and extensive use of measles-mumps-rubella
(MMR) vaccine (3 ). In 1980, stronger recommendations called for the vaccination of
susceptible* children, adolescents, and adults, unless such vaccination was contrain-
dicated (4 ). Following these increasingly comprehensive recommendations and the
enactment of state laws requiring mumps vaccination for school entry and atten-
dance, the reported incidence of mumps declined steadily. However, during 1986 and
1987, large outbreaks occurred among underimmunized cohorts of persons born dur-
ing 1967–1977, resulting in a shift in peak incidence from persons 5–9 years of age to
persons 10–19 years of age (5 ). In 1989, ACIP recommended that a second dose of
measles-containing vaccine be administered to children 4–6 years of age (at time of
entry to kindergarten or first grade), and designated MMR as the vaccine of choice (6 ).
This report is a summary of mumps surveillance data in the United States for 1988–
1993. Surveillance data from earlier time periods have been published previously
(7,8).
METHODS
Incidence rates for mumps were calculated from weekly reports of cases sent to
CDC’s National Notifiable Disease Surveillance System (NNDSS). Cases were reported
from 49 areas (i.e., 48 states and the District of Columbia); mumps was not a report-
able disease in Mississippi and Rhode Island during 1988 and in New Mexico and
Oregon during 1988–1993. Reports of outbreaks also were received sporadically
throughout the entire time period.
Population estimates for 1988–1993 were based on 1990 U.S. census data. The U.S.
Department of Health and Human Services provided information on state immuniza-
tion requirements.
Reports of mumps cases were analyzed to determine the distribution of patients by
age, race, and ethnicity; the month of report; and the reporting area. Accurate informa-
tion concerning the race and ethnicity of patients was not available for 1988 and 1989;
however, these variables were reported by 41 states in 1990, 38 in 1991, 34 in 1992,
and 43 in 1993. This report includes race and ethnicity data from 28 states in which
such data were reported for >50% of cases during each of these 4 years.
*Not known to have become immune to mumps by either natural or artificial means.
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RESULTS
General Trends
Except for a minimal increase in 1989, the incidence of mumps continued to decline
during 1988–1993, from 2.0 per 100,000 population in 1988 to 0.7 per 100,000 popula-
tion in 1993 (Figure 1). Only 1,692 mumps cases were reported for 1993; this was the
lowest number ever reported to NNDSS and a 99% reduction from the 152,209 cases
reported for 1968.
Incidence by Age Groups of Patients
During 1988–1993, patient age was reported for 85% of cases (Table 1). During
1991–1993, mumps incidence rates decreased in all age groups from rates for 1988–
1990; the largest decreases (i.e., >50% reductions) occurred among persons
10–19 years of age and among children <1 year of age (Table 2). From 1988 through
1991, annual incidence rates for children ages 10–14 years (5.3–7.8 per 100,000) ex-
ceeded those for children ages 5–9 years (4.5–6.6 per 100,000) (Figure 2). In 1992 and
1993, incidence rates for children ages 5–9 years were minimally higher than those for
children ages 10–14 years (3.2 vs. 2.6 per 100,000 in 1992, and 2.8 vs. 1.9 per 100,000
in 1993).
During the entire period, an average of 52% (range: 47%–55%) of reported cases for
which patient age was known occurred in children ages 5–14 years; 36% (range: 31%–
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†Licensed in December 1967.
FIGURE 1. Reported mumps incidence rates,* 1968–1993, and number of mumps
cases, 1988–1993, by year of report — United States





















1988 1989 1990 1991 1992 1993 Total
No. % No. % No. % No. % No. % No. % No. %
   <1    61  1.5   106  2.1    40  0.9    23  0.7  36  1.7  14  0.9   280  1.3
  1–4   392  9.4   438  8.8   504 11.1   381 11.5 342 15.8 284 17.6 2,341 11.3
  5–9 1,022 24.5 1,194 24.0 1,068 23.5   811 24.4 572 26.4 497 30.8 5,164 24.8
10–14 1,284 30.7 1,324 26.7 1,312 28.9   900 27.1 442 20.4 316 19.6 5,578 26.8
15–19   861 20.6 1,198 24.1   948 20.9   639 19.2 394 18.2 186 11.5 4,226 20.3
  ≥20   559 13.4   706 14.2   671 14.8   573 17.2 384 17.7 319 19.7 3,212 15.4
Age known 4,179 100.0 4,966 100.0 4,543 100.0 3,327 100.0 2,170  100.0 1,616  100.0 20,801 100.0 
Age unknown   687 —   746 —   749 —   937 — 402 —  76 — 3,597 —
Total 4,866 — 5,712 — 5,292 — 4,264 — 2,572  — 1,692  — 24,398 
* Includes the District of Columbia. Excludes states not reporting mumps cases (i.e., New Mexico and Oregon, 1988–1993; Mississippi and Rhode Island, 1988).
(Table 1). The remaining 1% of cases occurred in children <1 year of age. Although this
pattern was similar throughout the 6-year period, a smaller proportion of cases oc-
curred in children ages 5–14 years in 1993 compared with 1988 (50% and 55%,
respectively) and in persons ages 15–19 years (12% and 21%, respectively). A larger
TABLE 2. Age-specific mumps incidence rates* during selected periods, by age
group — United States†
Percentage change
Age group







    <1  2.4 1.7 0.6 (–29.2) (–64.7)
  1–4  4.1 3.0 2.3 (–26.8) (–23.3)
  5–9  9.7 6.1 3.5 (–37.1) (–42.6)
10–14 16.9 7.7 3.3 (–54.4) (–57.1)
15–19 10.3 5.6 2.3 (–45.6) (–58.9)
  ≥20  0.4 0.4 0.2 — (–50.0)
Total  3.7 2.2 1.1 (–40.5) (–50.0)
Incidence rates  
*Per 100,000 population.
†Includes the District of Columbia. Excludes states not reporting mumps cases (i.e., New Mexico
and Oregon, 1985–1993; Mississippi, 1985–1988; Oklahoma, 1985–1987; Rhode Island, 1988).



















FIGURE 2. Age-specific mumps incidence rates*, by year and age group — United
States, 1988–1993
Vol. 44 / No. SS-3 MMWR 5
proportion of cases occurred in children ages 1–4 years (18% and 9%, respectively)
and in persons ages ≥20 years (20% and 13%, respectively). 
Incidence by Race/Ethnicity of Patients
During 1990–1993, race and ethnicity were reported for approximately two thirds of
cases in each of 28 states and the District of Columbia. Mumps incidence decreased
for all races during this 4-year period. For each year, the highest incidence was among
black persons, ranging from 1.2 to 8.2 times the incidence of any other racial group. In
every age group, incidence rates for black persons exceeded rates for the other racial
groups; this relationship was most notable for persons 5–19 years of age (Figure 3).
Although incidence rates for Hispanics exceeded the rates for non-Hispanics in
every age group, the differences in rates were minimal for children <5 years of age
and for persons ≥20 years of age (Figure 4). The greatest difference in incidence rates
between Hispanics and non-Hispanics were for persons 5–19 years of age. 
State Immunization Laws
Comprehensive state immunization laws for mumps require documentation of vac-
cination for all children attending school (i.e., kindergarten through grade 12 [grades
K–12]); partial immunization laws require documentation of vaccination for selected
groups of children (i.e., at entry to school or at grades K–5, K–6, or K–10). During 1988–
1993, the number of states that had adopted comprehensive immunization laws
increased from 16 to 40 (Table 3). In 1993, only four states had partial immunization
laws, and seven other states, including a state that did not report mumps cases, had



















†From 29 areas reporting race for >50% of cases.
FIGURE 3. Average annual mumps incidence rates*, by age group and race — United
States,† 1990–1993

















†From 29 areas reporting ethnicity for >50% of cases.
FIGURE 4. Average annual mumps incidence rates*, by age group and ethnicity—
United States,† 1990–1993
TABLE 3. Reported mumps incidence rates*  for persons 5–19 years of age, by type of
state immunization requirements† — United States,§ 1988–1993
State immunization requirements
No laws¶ Partial laws** Comprehensive laws††
Year No. of states
Incidence
rate No. of states
Incidence
rate No. of states
Incidence
rate
1988 14 11.2 19 6.7 16 5.9
1989 11 13.2 19 7.9 21 4.7
1990 11 18.7 19 5.5 21 3.9
1991  8  6.8  5 6.1 38 4.0
1992  8  2.8  5 4.8 38 2.3
1993  7  3.7  4 1.3 40 1.8
Total mean  9.4 5.4 3.8
% decrease§§ (67.0) (80.6) (69.5) 
 *Cases per 100,000 population, adjusted for states not reporting mumps (i.e., New Mexico
and Oregon, 1988–1993; Mississippi and Rhode Island, 1988).
†Requirements represent classifications at the beginning of the calendar year. 
§Includes the District of Columbia.
¶No requirement for mumps vaccination before entering school.
**Includes some children but not all children in kindergarten through grade 12 (grades K–12);
California excluded for 1988 because information concerning age was not available.
††Requires proof of immunity (i.e., documentation of vaccination or previous mumps infection)
before entering school (e.g., day care, Head Start, and grades K–12).
§§Incidence rates for 1993 compared with those for 1988.
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In states that had comprehensive immunization laws during 1988–1993, the aver-
age annual incidence rate of mumps for persons of all ages was 1.3 cases per 100,000
population. In comparison, the reported incidence was 1.8 cases per 100,000 popula-
tion in states that had partial immunization laws and 2.9 cases per 100,000 population
in states that did not require mumps vaccination. For persons 5–19 years of age, the
average annual incidence rate per 100,000 population was 3.8 for states that had com-
prehensive immunization laws, 5.4 for states that had partial immunization laws, and
9.4 for states that did not require mumps vaccination (Table 3). In 1989, three of four
states and, in 1990, one of two states reporting >500 cases of mumps did not have
comprehensive immunization laws.
Geographic Distribution of Cases
In 1988, 1992, and 1993, no state reported >500 cases (Table 4). In 1989, four states
(i.e., California, Louisiana, Maryland, and Texas) each reported >500 cases. In 1990,
both California and Maryland reported >500 cases; in 1991, both California and Florida
reported 500 cases. In 1993, all but four states (i.e., Kentucky, Maine, Montana, and







*For students in kindergarten through grade 12 (grades K–12) and children in day care and
Head Start programs.
†Includes District of Columbia.
§Requires documentation of vaccination for all children attending school (i.e., grades K–12).
¶Requires documentation of vaccination for selected groups of children (i.e., at entry to school
or at grades K–5, K–6, or K–10.)
FIGURE 5. State immunization requirements* for measles, mumps and rubella (MMR)
— United States,† 1993–1994 school year















TABLE 4. Reported number of mumps cases and estimated incidence rates,* by state — United States, 1988–1993
1988 1989 1990 1991 1992 1993
1993 compared
with 1988 
(% change)State No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate
Alabama 16 0.4 29 0.7 19 0.5 15 0.4 14 0.3 22 0.5 (  37.5)
Alaska 13 2.5 2 0.4 6 1.1 18 3.2 3 0.5 11 1.8 ( –15.4)
Arizona 148 4.2 131 3.7 143 3.9 123 3.3 84 2.2 19 0.5 ( –87.2)
Arkansas 180 7.5 208 8.6 140 6.0 46 1.9 16 0.7 10 0.4 ( –94.4)
California 494 1.7 541 1.9 571 1.9 500 1.6 311 1.0 285 0.9 ( –42.3)
Colorado 33 1.0 86 2.6 28 0.9 136 4.0 34 1.0 18 0.5 ( –45.5)
Connecticut 10 0.3 11 0.3 17 0.5 14 0.4 8 0.2 8 0.2 ( –20.0)
Delaware 1 0.2 1 0.1 8 1.2 7 1.0 8 1.2 1 0.1     0.0
District of
Columbia 294 47.6 150 24.8 53 8.7 24 4.0 7 1.2 1 0.2 ( –99.7)
Florida 43 0.3 65 0.5 197 1.5 500 3.8 288 2.1 48 0.4 (  11.6)
Georgia 37 0.6 87 1.4 98 1.5 87 1.3 84 1.2 20 0.3 ( –45.9)
Hawaii 18 1.6 20 1.8 26 2.3 30 2.6 28 2.4 30 2.6 (  66.7)
Idaho 11 1.1 40 3.9 137 13.6 13 1.3 4 0.4 6 0.5 ( –45.5)
Illinois 348 3.0 218 1.9 205 1.8 166 1.4 128 1.1 74 0.6 ( –78.7)
Indiana 84 1.5 49 0.9 27 0.5 7 0.1 12 0.2 8 0.1 ( –90.5)
Iowa 43 1.5 54 1.9 22 0.8 24 0.9 13 0.5 11 0.4 ( –74.4)
Kansas 205 8.2 297 11.8 91 3.7 31 1.2 3 0.1 1 0.0 ( –99.5)
Kentucky 185 5.0 9 0.2 0 0.0 0 0.0 4 0.1 0 0.0 (–100.0)
Louisiana 365 8.3 783 17.9 118 2.8 37 0.9 35 0.8 20 0.5 ( –94.5)
Maine 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0     0.0
Maryland 204 4.4 603 12.8 1,141 23.9 249 5.1 93 1.9 82 1.7 ( –59.8)
Massachusetts 17 0.3 57 1.0 14 0.2 3 0.1 3 0.1 1 0.0 ( –94.1)
Michigan 236 2.6 161 1.7 177 1.9 121 1.3 85 0.9 80 0.8 ( –66.1)





87 3.3 28 1.1 23 0.9 33 1.3 17 0.6     NA
Missouri 68 1.3 87 1.7 62 1.2 40 0.8 39 0.8 46 0.9 ( –32.4)
Montana 2 0.2 4 0.5 1 0.1 0 0.0 2 0.2 0 0.0 (–100.0)
Nebraska 11 0.7 6 0.4 0 0.0 9 0.6 7 0.4 1 0.1 ( –90.9)
Nevada 16 1.5 7 0.6 18 1.5 19 1.5 14 1.1 27 1.9 (  68.8)
New Hampshire 106 9.8 15 1.4 11 1.0 6 0.5 8 0.7 3 0.3 ( –97.2)
New Jersey 57 0.7 214 2.8 104 1.3 43 0.6 18 0.2 17 0.2 ( –70.2)


















TABLE 4. Reported number of mumps cases and estimated incidence rates,* by state — United States, 1988–1993
1988 1989 1990 1991 1992 1993
1993 compared
with 1988 
(% change)State No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate
New York
 (excluding NYC¶) 110 1.0 176 1.7 161 1.5 111 1.0 88 0.8 46 0.4 ( –58.2)
 NYC 0 0.0 22 0.3 65 0.9 14 0.2 12 0.2 2 0.0     0.0
N. Carolina 52 0.8 45 0.7 325 4.9 269 4.0 219 3.2 231 3.3 ( 344.2)
N. Dakota 0 0.0 0 0.0 0 0.0 2 0.3 4 0.6 6 0.9     0.0
Ohio 144 1.3 165 1.5 91 0.8 112 1.0 117 1.1 74 0.7 ( –48.6)
Oklahoma 250 7.7 211 6.5 119 3.8 16 0.5 21 0.7 13 0.4 ( –94.8)
Oregon NN NA NN NA NN NA NN NA NN NA NN NA     NA
Pennsylvania 128 1.1 88 0.7 144 1.2 132 1.1 87 0.7 70 0.6 ( –45.3)
Rhode Island NN NA 0 0.0 10 1.0 4 0.4 2 0.2 2 0.2     NA
S. Carolina 9 0.3 56 1.6 76 2.2 402 11.3 52 1.4 17 0.5 (  88.9)
S. Dakota 1 0.1 0 0.0 0 0.0 2 0.3 0 0.0 0 0.0 (–100.0)
Tennessee 214 4.4 89 1.8 56 1.1 189 3.8 15 0.3 19 0.4 ( –91.1)
Texas 327 1.9 551 3.2 470 2.8 363 2.1 388 2.2 231 1.3 ( –29.4)
Utah 9 0.5 14 0.8 14 0.8 16 0.9 24 1.3 6 0.3 ( –33.3)
Vermont 6 1.1 3 0.5 2 0.4 4 0.7 2 0.4 1 0.2 ( –83.3)
Virginia 139 2.3 125 2.0 108 1.7 70 1.1 58 0.9 40 0.6 ( –71.2)
Washington 44 0.9 59 1.2 66 1.4 178 3.5 18 0.4 14 0.3 ( –68.2)
W. Virginia 19 1.0 19 1.0 44 2.5 30 1.7 31 1.7 23 1.3 (  21.1)
Wisconsin 160 3.3 57 1.2 60 1.2 33 0.7 21 0.4 23 0.5 ( –85.6)
Wyoming 7 1.5 8 1.7 3 0.7 5 1.1 1 0.2 5 1.1 ( –28.6)
Total 4,866 2.0 5,712 2.3 5,292 2.2 4,264 1.7 2,572 1.0 1,692 0.7 ( –65.2)
* Per 100,000 population.
† Not notifiable.
§ Not applicable.
¶ New York City.
Seasonality
During 1988–1993, mumps incidence, as determined by month of reporting, was
consistently highest during winter and early spring and lowest during the summer
(data not shown). This seasonal trend did not change during the 6 reporting years,
despite the overall decline in mumps incidence during this time period. 
DISCUSSION
Since the introduction of mumps vaccine in the United States in 1967, several de-
velopments have contributed substantially to the 99% reduction in mumps incidence.
These developments include a) an increasingly inclusive vaccination policy; b) the
1989 ACIP recommendation for a two-dose measles vaccination schedule, designat-
ing MMR as the preferred vaccine; and c) the enactment, in an increasing number of
states since 1977, of state immunization laws that require mumps vaccination for
school attendance. The introduction of mumps vaccine was associated with both an
overall decline in reported disease incidence and a change in the epidemiology of the
disease.
During the prevaccine era and for >10 years after vaccine licensure, the risk for
mumps was highest among children 5–9 years of age. During the 1980s, concomitant
with an overall decline in the incidence of mumps, the proportion of cases occurring
in older children and adolescents increased (7–9 ). In 1980, ACIP had recommended
vaccination for all susceptible children (i.e., no clinical history of disease), adolescents,
and adults unless contraindicated (4 ). Nevertheless, during 1986 and 1987, outbreaks
occurred among susceptible adolescents and young adults in high schools and col-
leges (10–13 ), hospitals (14,15 ), and in work places where persons are in close
contact (16 ). This trend reflected underimmunization of the cohort born from 1967
through 1977, a period when vaccine was not administered routinely to children and
the risk for exposure to mumps was decreasing. Thus, the age associated with the
highest incidence shifted from children of school ages to older children, adolescents,
and young adults. A less pronounced shift in incidence by age also occurred in 1982
(11 ).
The incidence of mumps during 1988–1993 decreased among all age groups. The
greatest decrease occurred among persons 10–19 years of age—the same ages at
which the greatest increases had occurred during 1986 and 1987, when a resurgence
of outbreaks occurred among susceptible adolescents and young adults (10–16 ). Sub-
sequent outbreaks have occurred among highly vaccinated populations. During
1989–1990, a large outbreak occurred among students in a primary and a secondary
school; most of the students in these schools had been vaccinated, suggesting that
vaccination failure, in addition to failure to vaccinate, might have contributed to the
outbreak (17 ). In 1991, another outbreak occurred in a secondary school where most
of the students had been vaccinated; this outbreak also was mostly attributed to pri-
mary vaccination failure (18 ).
The shift in higher risk for mumps to these other age groups (i.e., from younger
children of school ages to older children, adolescents, and young adults)—which
occurred after the routine use of mumps vaccine was initiated—has persisted despite
minimal fluctuations in disease incidence that occurred in recent years among the
various age groups. The age distribution of persons who had mumps during 1988–
1993 was similar to that of the 3 preceding years (8 ). Although the majority of cases
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during 1988–1993 (52%) and 1985–1987 (58%) occurred in children 5–14 years of age,
a higher proportion (75%) was reported in this age group during the 5 years after vac-
cine licensure (i.e., 1967–1971) and before the routine administration of mumps
vaccine (11 ). Conversely, an increasingly larger proportion of cases in persons
≥15 years of age have been reported in recent periods (i.e., 1967–1971, 8%; 1985–1987,
28%; 1988–1993, 36%).
The large decrease in the incidence of mumps during 1988–1993 also might reflect
the change in the recommended use of MMR. In 1989, after the resurgence of measles
among children of school ages during the late 1980s, ACIP recommended a two-dose
measles vaccination schedule using MMR as the preferred vaccine (6 ). The imple-
mentation of the two-dose MMR vaccination schedule, with the second dose
administered at 4–6 years or at 11–12 years (6,19 ), probably affected the incidence of
mumps by conferring immunity to children who had had primary vaccination failure.
The single most important measure for reducing mumps incidence has been the
enactment of state immunization laws requiring that students be vaccinated
(7,8,11,20 ). States with comprehensive immunization laws had lower incidence rates
for mumps than states without such laws; the highest incidence rates occurred in
states with no laws, and intermediate incidence rates were reported from states with
partial laws. In addition, the shift in the age distribution of patients that was noted
during the mumps outbreaks of the 1980s occurred only in states with partial or no
school immunization laws (11 ).
Although the association between mumps incidence rates and state immunization
laws during 1993 did not differ from that in 1988, the number of states that had com-
prehensive immunization laws more than doubled, and this probably contributed to
the 65% decrease in the national incidence of mumps during 1993 in comparison with
1988. For example, Tennessee adopted a comprehensive immunization law in Sep-
tember 1988 and noted a 91% decrease in the incidence of mumps during 1993 in
comparison with 1988.
Mumps incidence rates also decreased in the seven states that did not have immu-
nization laws. These decreases might be attributed partially to the decreased number
of cases in states that had immunization laws, which likely resulted in decreased virus
transmission to persons in neighboring states that did not have such laws. Similarly,
the decreased number of cases in infants and children of preschool ages probably
reflects the decreased transmission in families as a result of the reduced incidence
among children of school ages.
During 1990–1993, mumps incidence decreased among all racial groups. However,
incidence rates were higher for black persons, particularly for those 5–19 years of age.
In areas without state immunization requirements for school attendance, the higher
incidence rate of mumps for blacks may reflect lower vaccination rates for black chil-
dren in comparison with white children and adolescents (5 ).
Although overall incidence rates for mumps declined, the seasonal pattern for
1988–1993 remained consistent with the pattern characteristic of earlier prevaccine
and postvaccine licensure periods (7–9 ).
The mumps surveillance data for 1988–1993 have certain inherent limitations. Be-
cause the NNDSS depends on passive reporting, iadditional validation studies are
required to estimate the completeness of reporting and accuracy of the data collected.
Furthermore, the association between increased mumps vaccine coverage and de-
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creased mumps incidence could not be confirmed because vaccination status of pa-
tients was not reported to NNDSS.
From 1967 through 1993, an estimated 137 million doses of mumps vaccine (as
MMR, monovalent mumps, or other combined vaccines) were distributed in the
United States. The vaccine is safe, efficacious, and cost-beneficial in preventing
mumps illness (21–23 ). Groups other than ACIP also have recommended mumps im-
munization; these groups include the American Academy of Pediatrics, which
recommends mumps vaccination of children and adolescents (19 ), and the American
College Health Association (ACHA), which recommends requiring that all students
born after 1956 present documentation of vaccination against mumps before matricu-
lation (24 ).
Several approaches would ensure that high rates of vaccination are maintained
and transmission of mumps is controlled. First, all health-care providers are encour-
aged to report mumps cases to their local and state health departments for
transmission to NNDSS. Reporting of additional data, including vaccination status, via
CDC’s National Electronic Telecommunication System for Surveillance (NETSS) is cur-
rently being implemented. Second, all states are encouraged to enact comprehensive
school immunization laws, if they have not already done so, to ensure that all students
receive at least one dose of mumps vaccine. States should continue to implement the
two-dose measles vaccination policy, using MMR for both doses, to further decrease
mumps susceptibility. Third, other groups that are responsible for populations at risk
for mumps (e.g., employers) are encouraged to adopt requirements similar to ACHA’s
recommendations (24 ). Fourth, recommended outbreak control measures for mumps
(e.g., exclusion policies for susceptible students) should be applied more aggressively
(25 ).
As part of the Childhood Immunization Initiative, the national reduction goal for
mumps (i.e., the maximum number of cases expected) for 1996 is 1,600 cases. Al-
though the number of mumps cases reported for 1993 reflects achievement of this
objective, the incidence could increase as a result of importation of cases and the in-
creasing emphasis on surveillance.
CONCLUSION
Incidence rates for mumps in the United States have declined substantially since
the licensure and widespread use of mumps vaccine. Policies for providing routine
vaccination of young children, policies targeting older populations at risk, and the en-
actment of school immunization laws have all contributed to the decrease in mumps
incidence. During 1988–1993, the incidence of mumps decreased further after the
number of states with immunization laws increased and the two-dose vaccination
schedule for measles using MMR was initiated.
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